trial_id
stringlengths 11
11
| question
stringlengths 154
5.24k
| options
dict | answer
stringclasses 4
values | trials
listlengths 4
4
| id
int64 0
27.3k
| split
stringclasses 2
values |
|---|---|---|---|---|---|---|
NCT00000611
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ethinylestradiol / Norethisterone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol / Progesterone | Intervention Type: DRUG; Name: Ethinylestradiol / Norethisterone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Estradiol / Progesterone; Assigned to Arm(s): 2",
"B": "Arm Label: 4 mg estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol | Arm Label: 2 mg estradiol; Type: PLACEBO_COMPARATOR; Interventions: Drug: estradiol | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): 2 mg estradiol, 4 mg estradiol",
"C": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"D": "Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 B estradiol orally | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 B estradiol | Intervention Type: DRUG; Name: 17 B estradiol orally; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: 17 B estradiol; Assigned to Arm(s): Group B"
}
|
C
|
[
"NCT00732693",
"NCT00134745",
"NCT00000611",
"NCT00837616"
] | 100 |
train
|
NCT00000611
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
|
{
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices",
"C": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"D": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Caloric Restriction; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention | Arm Label: Exercise Intervention; Type: OTHER; Interventions: Behavioral: Exercise intervention | Arm Label: Caloric Restriction AND Exercise Intervention; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention, Behavioral: Exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Caloric Restriction, Caloric Restriction AND Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Exercise intervention; Assigned to Arm(s): Caloric Restriction AND Exercise Intervention, Exercise Intervention"
}
|
A
|
[
"NCT00000611",
"NCT01017783",
"NCT00000616",
"NCT00470119"
] | 101 |
train
|
NCT00000615
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in African-American girls who are at high risk for developing obesity.
|
{
"A": "Arm Label: Consumer Support; Type: EXPERIMENTAL; Interventions: Other: Control condition | Arm Label: Consumer Support with Effectiveness Info; Type: EXPERIMENTAL; Interventions: Other: Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages | Intervention Type: OTHER; Name: Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages; Assigned to Arm(s): Consumer Support with Effectiveness Info | Intervention Type: OTHER; Name: Control condition; Assigned to Arm(s): Consumer Support",
"B": "Intervention Type: BEHAVIORAL; Name: Nurtition and Physical Activity Education; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A",
"D": "Arm Label: Calorie Label; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: Warning Label; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: Warning Label with Graphics; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: No label; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Label Condition; Assigned to Arm(s): Calorie Label, Warning Label, Warning Label with Graphics"
}
|
C
|
[
"NCT02947802",
"NCT00153322",
"NCT00000615",
"NCT02744859"
] | 102 |
train
|
NCT00000615
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in African-American girls who are at high risk for developing obesity.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A",
"B": "Arm Label: \"Fortaleça sua Saúde\" program; Type: EXPERIMENTAL; Interventions: Behavioral: \"Fortaleça sua Saúde\" program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: \"Fortaleça sua Saúde\" program; Assigned to Arm(s): \"Fortaleça sua Saúde\" program",
"C": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Arm Label: High dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Intervention Type: BEHAVIORAL; Name: Aerobic exercise program; Assigned to Arm(s): High dose, Low Dose",
"D": "Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program"
}
|
A
|
[
"NCT00000615",
"NCT02439827",
"NCT00108901",
"NCT01704768"
] | 103 |
train
|
NCT00000615
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in African-American girls who are at high risk for developing obesity.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A",
"B": "Arm Label: NewNordicDiet first; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Arm Label: NewNordicDiet last; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Intervention Type: OTHER; Name: School meals based on the principles of the New Nordic Diet; Assigned to Arm(s): NewNordicDiet first, NewNordicDiet last",
"C": "Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program",
"D": "Arm Label: Breakfast Skipping; Type: EXPERIMENTAL; Interventions: Behavioral: Breakfast Skipping | Arm Label: Normal Protein Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Normal Protein Breakfast Meals | Arm Label: Protein-rich Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Protein-rich Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Breakfast Skipping; Assigned to Arm(s): Breakfast Skipping | Intervention Type: BEHAVIORAL; Name: Normal Protein Breakfast Meals; Assigned to Arm(s): Normal Protein Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Protein-rich Breakfast Meals; Assigned to Arm(s): Protein-rich Breakfast Meals"
}
|
A
|
[
"NCT00000615",
"NCT01457794",
"NCT01704768",
"NCT01192100"
] | 104 |
train
|
NCT00000615
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in African-American girls who are at high risk for developing obesity.
|
{
"A": "Arm Label: Low intensity arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, physical activity and sleeping | Arm Label: High intensity arm; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, physical activity and sleeping | Intervention Type: BEHAVIORAL; Name: Dietary, physical activity and sleeping; Assigned to Arm(s): High intensity arm, Low intensity arm",
"B": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: School children and adolescents as health experts | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School children and adolescents as health experts; Assigned to Arm(s): A",
"C": "Arm Label: Tools for Teen Moms Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tools for Teen Moms | Arm Label: MIHP standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tools for Teen Moms; Assigned to Arm(s): Tools for Teen Moms Intervention Group",
"D": "Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT01198847",
"NCT00988754",
"NCT02244424",
"NCT00000615"
] | 105 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)",
"B": "Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo",
"C": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT01005498",
"NCT00069784",
"NCT00000616",
"NCT00000611"
] | 106 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"B": "Arm Label: Low Fat Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Fat Diet | Arm Label: Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Mediterranean Diet; Assigned to Arm(s): Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Low Fat Diet; Assigned to Arm(s): Low Fat Diet",
"C": "Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DASH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Approaches to Stop Hypertension dietary pattern | Intervention Type: BEHAVIORAL; Name: Dietary Approaches to Stop Hypertension dietary pattern; Assigned to Arm(s): DASH Intervention",
"D": "Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00000616",
"NCT00924937",
"NCT01725945",
"NCT00230919"
] | 107 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-fat diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Low-fat diet; Assigned to Arm(s): 2",
"B": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet",
"C": "Arm Label: Experimental diet; Type: EXPERIMENTAL; Interventions: Other: Experimental diet | Arm Label: Control diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control diet | Intervention Type: OTHER; Name: Experimental diet; Assigned to Arm(s): Experimental diet | Intervention Type: OTHER; Name: Control diet; Assigned to Arm(s): Control diet",
"D": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00725257",
"NCT00622960",
"NCT00992641",
"NCT00000616"
] | 108 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Caloric Restriction; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention | Arm Label: Exercise Intervention; Type: OTHER; Interventions: Behavioral: Exercise intervention | Arm Label: Caloric Restriction AND Exercise Intervention; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention, Behavioral: Exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Caloric Restriction, Caloric Restriction AND Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Exercise intervention; Assigned to Arm(s): Caloric Restriction AND Exercise Intervention, Exercise Intervention",
"B": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A",
"D": "Intervention Type: BEHAVIORAL; Name: Weight reduction, Resistance training, Aerobic exercise training, Control; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00470119",
"NCT00000616",
"NCT00124553",
"NCT00621205"
] | 109 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: artificially sweetened beverages | Intervention Type: DIETARY_SUPPLEMENT; Name: artificially sweetened beverages; Assigned to Arm(s): intervention group",
"B": "Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water",
"C": "Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement",
"D": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT03679689",
"NCT00777647",
"NCT00779571",
"NCT00000616"
] | 110 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"B": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet",
"C": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00000616",
"NCT00622960",
"NCT00003787",
"NCT00000611"
] | 111 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: Intervention - PilAm Go4Health Program; Type: EXPERIMENTAL; Interventions: Behavioral: PilAm Go4Health Weight-loss Program | Arm Label: Active control - pedometer only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: PilAm Go4Health Weight-loss Program; Assigned to Arm(s): Intervention - PilAm Go4Health Program | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active control - pedometer only",
"B": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"C": "Arm Label: No calorie beverages; Type: EXPERIMENTAL; Interventions: Behavioral: 2 no calorie beverages per day | Arm Label: Water; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 water beverages per day | Intervention Type: BEHAVIORAL; Name: 2 no calorie beverages per day; Assigned to Arm(s): No calorie beverages | Intervention Type: BEHAVIORAL; Name: 2 water beverages per day; Assigned to Arm(s): Water",
"D": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rewards; Type: EXPERIMENTAL; Interventions: Behavioral: F&V Bonus | Arm Label: Restrictions; Type: EXPERIMENTAL; Interventions: Behavioral: Restriction | Arm Label: Rewards plus restrictions; Type: EXPERIMENTAL; Interventions: Behavioral: Bonus & Restriction | Intervention Type: BEHAVIORAL; Name: F&V Bonus; Assigned to Arm(s): Rewards | Intervention Type: BEHAVIORAL; Name: Restriction; Assigned to Arm(s): Restrictions | Intervention Type: BEHAVIORAL; Name: Bonus & Restriction; Assigned to Arm(s): Rewards plus restrictions"
}
|
B
|
[
"NCT02290184",
"NCT00000616",
"NCT01766700",
"NCT02643576"
] | 112 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"D": "Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline"
}
|
C
|
[
"NCT00160108",
"NCT00000611",
"NCT00000616",
"NCT02062424"
] | 113 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet",
"B": "Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2",
"D": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00622960",
"NCT00274729",
"NCT00276939",
"NCT00000616"
] | 114 |
train
|
NCT00000616
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
|
{
"A": "Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group",
"B": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"C": "Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices",
"D": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT01470222",
"NCT00000611",
"NCT01017783",
"NCT00000616"
] | 115 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Blood pressure; Type: EXPERIMENTAL; Interventions: Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone | Intervention Type: DRUG; Name: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone; Assigned to Arm(s): Blood pressure",
"B": "Arm Label: SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: OTHER; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Intervention Type: DRUG; Name: all approved antihypertensive drugs; all approved statins; Assigned to Arm(s): SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 125 mmHg and LDL-C < 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l",
"C": "Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT01198496",
"NCT01563731",
"NCT01650402",
"NCT00000620"
] | 116 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"B": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"C": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"D": "Arm Label: BIAsp 30; Type: EXPERIMENTAL; Interventions: Drug: BIAsp 30 | Arm Label: NPH/Reg; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH/Reg | Intervention Type: DRUG; Name: BIAsp 30; Assigned to Arm(s): BIAsp 30 | Intervention Type: DRUG; Name: NPH/Reg; Assigned to Arm(s): NPH/Reg"
}
|
C
|
[
"NCT00032487",
"NCT00145925",
"NCT00000620",
"NCT01889095"
] | 117 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"B": "Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A",
"C": "Arm Label: SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: OTHER; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Intervention Type: DRUG; Name: all approved antihypertensive drugs; all approved statins; Assigned to Arm(s): SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 125 mmHg and LDL-C < 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l",
"D": "Arm Label: Intensive Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Arm Label: Usual Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Intervention Type: DRUG; Name: Triatec 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec HCT 5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Lasix 25; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis 80 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis plus 80/12.5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Catapresan TTS 2; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Norvasc 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec 5 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Pluscor; Assigned to Arm(s): Intensive Strategy, Usual Strategy"
}
|
A
|
[
"NCT00000620",
"NCT00133692",
"NCT01563731",
"NCT00421863"
] | 118 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Observation (Prompt Sham); Type: SHAM_COMPARATOR; Interventions: Procedure: Prompt Sham, Procedure: Deferred laser, Drug: Deferred aflibercept | Arm Label: Prompt aflibercept; Type: EXPERIMENTAL; Interventions: Drug: Prompt aflibercept, Procedure: Deferred laser, Drug: Deferred aflibercept | Intervention Type: PROCEDURE; Name: Prompt Sham; Assigned to Arm(s): Observation (Prompt Sham) | Intervention Type: DRUG; Name: Prompt aflibercept; Assigned to Arm(s): Prompt aflibercept | Intervention Type: PROCEDURE; Name: Deferred laser; Assigned to Arm(s): Observation (Prompt Sham), Prompt aflibercept | Intervention Type: DRUG; Name: Deferred aflibercept; Assigned to Arm(s): Observation (Prompt Sham), Prompt aflibercept",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal aflibercept injection [IAI] | Arm Label: Dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal aflibercept injection [IAI] | Arm Label: Dosing regimen 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham | Intervention Type: DRUG; Name: Intravitreal aflibercept injection [IAI]; Assigned to Arm(s): Dosing regimen 1, Dosing regimen 2 | Intervention Type: DRUG; Name: Sham; Assigned to Arm(s): Dosing regimen 3",
"D": "Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP"
}
|
B
|
[
"NCT02634333",
"NCT00000620",
"NCT02718326",
"NCT01489189"
] | 119 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"B": "Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Glucagon-like peptide-1 (GLP-1); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Glucagon-like peptide-1 (GLP-1), Other: Hyperglycemic clamp | Arm Label: Isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Isotonic saline, Other: Hyperglycemic clamp | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucagon-like peptide-1 (GLP-1); Assigned to Arm(s): Glucagon-like peptide-1 (GLP-1) | Intervention Type: OTHER; Name: Isotonic saline; Assigned to Arm(s): Isotonic saline | Intervention Type: OTHER; Name: Hyperglycemic clamp; Assigned to Arm(s): Glucagon-like peptide-1 (GLP-1), Isotonic saline"
}
|
A
|
[
"NCT00000620",
"NCT03157414",
"NCT01394952",
"NCT02591849"
] | 120 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A",
"B": "Arm Label: SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: OTHER; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Intervention Type: DRUG; Name: all approved antihypertensive drugs; all approved statins; Assigned to Arm(s): SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 125 mmHg and LDL-C < 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l",
"C": "Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT00122811",
"NCT01563731",
"NCT01650402",
"NCT00000620"
] | 121 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: intensive blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 120 mmHg | Arm Label: standard blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 140 mmHg | Intervention Type: DRUG; Name: control systolic blood pressure less than 120 mmHg; Assigned to Arm(s): intensive blood pressure control | Intervention Type: DRUG; Name: control systolic blood pressure less than 140 mmHg; Assigned to Arm(s): standard blood pressure control",
"B": "Arm Label: Standard treatment regimen; Type: EXPERIMENTAL; Interventions: Drug: valsartan, Drug: amlodipine | Arm Label: Intensive treatment regimen; Type: EXPERIMENTAL; Interventions: Drug: valsartan, Drug: amlodipine | Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): Intensive treatment regimen, Standard treatment regimen | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): Intensive treatment regimen, Standard treatment regimen",
"C": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"D": "Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A"
}
|
C
|
[
"NCT01230216",
"NCT00523549",
"NCT00000620",
"NCT01164371"
] | 122 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin | Arm Label: Alogliptin 12.5 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin and insulin | Arm Label: Alogliptin 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin and insulin | Intervention Type: DRUG; Name: Alogliptin and insulin; Assigned to Arm(s): Alogliptin 12.5 mg QD | Intervention Type: DRUG; Name: Alogliptin and insulin; Assigned to Arm(s): Alogliptin 25 mg QD | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin"
}
|
B
|
[
"NCT00954447",
"NCT00000620",
"NCT01582230",
"NCT00286429"
] | 123 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Vildagliptin, 50 mg, peroral; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vildagliptin | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin, 50 mg, peroral",
"D": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control"
}
|
B
|
[
"NCT00598013",
"NCT00000620",
"NCT00980356",
"NCT00145925"
] | 124 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor",
"B": "Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan",
"C": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"D": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo"
}
|
C
|
[
"NCT00129103",
"NCT00252720",
"NCT00000620",
"NCT00542178"
] | 125 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"B": "Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP",
"C": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT00145925",
"NCT01489189",
"NCT00542178",
"NCT00000620"
] | 126 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: intensive blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 120 mmHg | Arm Label: standard blood pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: control systolic blood pressure less than 140 mmHg | Intervention Type: DRUG; Name: control systolic blood pressure less than 120 mmHg; Assigned to Arm(s): intensive blood pressure control | Intervention Type: DRUG; Name: control systolic blood pressure less than 140 mmHg; Assigned to Arm(s): standard blood pressure control",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Aggressive BP lowering; Type: EXPERIMENTAL; Interventions: Procedure: Aggressive BP lowering | Arm Label: Modest BP lowering; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modest blood pressure lowering | Intervention Type: PROCEDURE; Name: Aggressive BP lowering; Assigned to Arm(s): Aggressive BP lowering | Intervention Type: PROCEDURE; Name: modest blood pressure lowering; Assigned to Arm(s): Modest BP lowering",
"D": "Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control"
}
|
B
|
[
"NCT01230216",
"NCT00000620",
"NCT01104311",
"NCT03015311"
] | 127 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: linagliptin 5mg; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin 5mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Linagliptin 5mg; Assigned to Arm(s): linagliptin 5mg",
"B": "Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT01792518",
"NCT01194830",
"NCT00542178",
"NCT00000620"
] | 128 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo",
"B": "Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A",
"C": "Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT00542178",
"NCT00143949",
"NCT00252694",
"NCT00000620"
] | 129 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A",
"B": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"C": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT00360815",
"NCT00032487",
"NCT00145925",
"NCT00000620"
] | 130 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Standard Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Arm Label: Intensive Treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Stop smoking; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Glucose lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Blood pressure lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Lipid lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm",
"B": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo",
"C": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"D": "N/A"
}
|
C
|
[
"NCT00320008",
"NCT00542178",
"NCT00000620",
"NCT00360893"
] | 131 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Glargine insulin; Type: EXPERIMENTAL; Interventions: Drug: Glargine insulin | Arm Label: NPH insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin | Intervention Type: DRUG; Name: Glargine insulin; Assigned to Arm(s): Glargine insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): NPH insulin",
"B": "Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose",
"C": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"D": "Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: \"Standard of care\" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): \"Standard of care\" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): \"Standard of care\" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): \"Standard of care\" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): \"Standard of care\" commercially available basal insulin"
}
|
C
|
[
"NCT02451917",
"NCT01131676",
"NCT00000620",
"NCT02967211"
] | 132 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet",
"B": "Arm Label: Intensive Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Arm Label: Usual Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Intervention Type: DRUG; Name: Triatec 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec HCT 5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Lasix 25; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis 80 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis plus 80/12.5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Catapresan TTS 2; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Norvasc 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec 5 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Pluscor; Assigned to Arm(s): Intensive Strategy, Usual Strategy",
"C": "Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
D
|
[
"NCT00059306",
"NCT00421863",
"NCT00133692",
"NCT00000620"
] | 133 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00047424",
"NCT00000620",
"NCT00133692",
"NCT00153101"
] | 134 |
train
|
NCT00000620
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
|
{
"A": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"D": "Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00032487",
"NCT00000620",
"NCT00145925",
"NCT00147758"
] | 135 |
train
|
NCT00000622
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo granules | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo granules; Assigned to Arm(s): 2",
"B": "Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A",
"C": "Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): montelukast",
"D": "Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00524693",
"NCT00000622",
"NCT00934713",
"NCT00076973"
] | 136 |
train
|
NCT00000622
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
|
{
"A": "Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mannitol | Arm Label: Montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): Montelukast"
}
|
B
|
[
"NCT00238927",
"NCT00000622",
"NCT00196547",
"NCT01142505"
] | 137 |
train
|
NCT00000622
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
|
{
"A": "Arm Label: Placebo Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide | Intervention Type: DRUG; Name: Placebo Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide",
"B": "Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A",
"C": "Arm Label: Beclomethasone dipropionate; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate | Arm Label: Beclomethasone dipropionate/Salbutamol combination; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate/Salbutamol combination | Arm Label: Salbutamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salbutamol | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Beclomethasone dipropionate | Intervention Type: DRUG; Name: Beclomethasone dipropionate/Salbutamol combination; Assigned to Arm(s): Beclomethasone dipropionate/Salbutamol combination | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Salbutamol",
"D": "Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00675584",
"NCT00238927",
"NCT00497523",
"NCT00000622"
] | 138 |
train
|
NCT00000622
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
|
{
"A": "Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Budesonide/formoterol; Assigned to Arm(s): N/A",
"C": "Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment",
"D": "Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00238927",
"NCT00290264",
"NCT00495157",
"NCT00000622"
] | 139 |
train
|
NCT00000622
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
|
{
"A": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1",
"B": "Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2",
"C": "Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A",
"D": "Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT00117338",
"NCT00565955",
"NCT00000622",
"NCT00092989"
] | 140 |
train
|
NCT00000622
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
|
{
"A": "Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2",
"D": "Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00454051",
"NCT00545844",
"NCT00461032",
"NCT00000622"
] | 141 |
train
|
NCT00000867
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Memantine for AIDS Dementia Complex (ADC) as Concurrent Treatment With Antiretroviral Therapy
Brief Summary: The purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving AIDS dementia complex (ADC).
The symptoms of ADC can be improved with zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, and the effectiveness of ZDV seems to decrease during the second and third years of therapy. The effectiveness of other antiretroviral drugs as treatment for ADC is not known, so it is important to explore alternative therapies.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2",
"B": "Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A",
"D": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4"
}
|
B
|
[
"NCT00505167",
"NCT00000867",
"NCT00300716",
"NCT00235716"
] | 142 |
train
|
NCT00000923
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART)
Brief Summary: This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART). The purpose of this study is to see if IL-2 can increase the number of CD4 cells (cells of the immune system which fight infection) in HIV-infected patients who have completed ACTG 328.
HAART is often successful in decreasing viral load (level of HIV in the blood), but these drugs have not been able to restore the immune systems of HIV-infected patients. IL-2 is a substance naturally produced by the body's immune cells. In ACTG 328, IL-2 is tested to see if it can increase the number of CD4 cells and "boost" a patient's immune system. This study is a follow-up to ACTG 328 so that patients who are benefiting from IL-2 can continue to take it and patients in the control group who do not receive IL-2 can start taking it.
|
{
"A": "Arm Label: Antiretroviral therapy alone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proleukin plus antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Drug: Proleukin | Intervention Type: DRUG; Name: Proleukin; Assigned to Arm(s): Proleukin plus antiretroviral therapy",
"B": "Arm Label: No IL-2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IL-2 without ART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Arm Label: IL-2 with pericycle HAART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Intervention Type: DRUG; Name: IL-2; Assigned to Arm(s): IL-2 with pericycle HAART, IL-2 without ART",
"C": "Arm Label: rIL-2; Type: EXPERIMENTAL; Interventions: Drug: Recombinant interleukin-2 (rIL-2) | Arm Label: No rIL-2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant interleukin-2 (rIL-2); Assigned to Arm(s): rIL-2",
"D": "Intervention Type: DRUG; Name: Indinavir sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00013611",
"NCT00110812",
"NCT00004978",
"NCT00000923"
] | 143 |
train
|
NCT00001174
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bipolar Genetics: A Collaborative Study
Brief Summary: This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions....
|
{
"A": "Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)",
"B": "Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment",
"C": "Arm Label: Less Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: More Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Less Dependent Smokers, More Dependent Smokers",
"D": "Arm Label: Healthy Volunteers; Type: N/A; Interventions: N/A | Arm Label: Patients; Type: N/A; Interventions: N/A"
}
|
D
|
[
"NCT01314001",
"NCT00364156",
"NCT00734617",
"NCT00001174"
] | 144 |
train
|
NCT00001195
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endocrine Studies of Healthy Children
Brief Summary: Researchers would like to determine normal ranges for hormone levels and to learn more about the genetics involved in hormone production and action. Researchers will take samples of blood, urine, saliva, and stool from healthy children ages 5-17 in order to study different aspects of hormones.
Establishing a range of normal hormone levels in children will make diagnosing illnesses with abnormal levels of hormones much easier. Hormone levels in the body can change throughout the day. By collecting samples at different times researchers hope to learn more about the normal daytime and nighttime patterns of hormone secretion. Because some hormone levels change with body size, researchers will also take measurements of patient's body composition.
This study will involve children and observe them as inpatients or as outpatients. \<TAB\>
|
{
"A": "Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol",
"B": "Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide",
"C": "N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Orlistat; Type: EXPERIMENTAL; Interventions: Drug: Orlistat | Intervention Type: DRUG; Name: Orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT01435278",
"NCT00886626",
"NCT00001195",
"NCT00001723"
] | 145 |
train
|
NCT00001221
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled Trial of the Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome
Brief Summary: Turners Syndrome is a genetic condition in females that is a result of abnormal chromosomes. Girls with Turner syndrome are very short as children and as adults. Although their growth hormone secretion is almost always normal, giving injections of growth hormone to Turner syndrome girls may increase their rate of growth. In addition, most girls with Turner syndrome do not have normal ovaries.
In normal girls the ovaries begin producing small amounts of the female sex hormone, estrogen at about 11 - 12 years of age. As girls grow older the level of estrogen increases. Estrogen is responsible for the changes in girls known as feminization. During feminization the hips grow wider, the breasts develop, there is an increase in the rate of growth, and eventually girls experience their first menstrual period.
This study was designed to evaluate the effect of low dose estrogen, growth hormone, and the combination of low dose estrogen and growth hormone on adult height in girls with Turner syndrome. Patients will be entered into the study from ages 5 to 12 and will be randomly placed into one of four groups.
1. Group one will receive low dose estrogen
2. Group two will receive growth hormone
3. Group three will receive both low dose estrogen and growth hormone
4. Group four will receive a placebo "sugar pill"
Once started, the treatment will continue until the patients approach their adult height, and growth slows to less than 1/2 inch over the preceding year. This usually occurs by the age of 15 or 16.
Patients will be seen at the outpatient clinic every 6 months during the study and will receive a routine check-up with blood and urine tests, and hand/wrist X-rays to determine bone age. On patient's yearly visits they will have the density of bone measured in their spine and forearm.
|
{
"A": "Arm Label: 4 mg estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol | Arm Label: 2 mg estradiol; Type: PLACEBO_COMPARATOR; Interventions: Drug: estradiol | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): 2 mg estradiol, 4 mg estradiol",
"B": "Intervention Type: DRUG; Name: Growth Hormone (Humatrope); Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ethinylestradiol / Norethisterone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol / Progesterone | Intervention Type: DRUG; Name: Ethinylestradiol / Norethisterone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Estradiol / Progesterone; Assigned to Arm(s): 2",
"D": "Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 B estradiol orally | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 B estradiol | Intervention Type: DRUG; Name: 17 B estradiol orally; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: 17 B estradiol; Assigned to Arm(s): Group B"
}
|
B
|
[
"NCT00134745",
"NCT00001221",
"NCT00732693",
"NCT00837616"
] | 146 |
train
|
NCT00001406
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eosinophil Activation and Function in Parasitic Infections and Other Conditions With Increased Tissue or Peripheral Blood Eosinophilia in Humans
Brief Summary: This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon autoimmune conditions and, rarely, in association with tumors. Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung problems, heart disease or nerve damage caused by the release of toxic substances in these cells into body tissues.
Patients 1 to 100 years of age with eosinophil counts greater than 750/ml or an abnormal accumulation of eosinophils in the skin or body tissues may be eligible for this study. All participants will have a thorough medical history, physical examination and blood tests. Depending on the person's age and symptoms, other diagnostic tests may be done, including specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a treatment study, and no experimental treatments will be offered. Patients who require treatment will receive standard medical care.
Certain other procedures may be requested solely for research purposes. All participants will be asked to donate extra blood for laboratory studies investigating how immune cells and other immune substances in the blood act to stimulate a rise in eosinophils. In addition, some participants may undergo one or more of the following:
* Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes in the patient's condition and eosinophil counts over time.
* Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and in certain patients at other times when it is important to look directly at the newly developing cells in the bone marrow. For this procedure an area of skin and bone is anesthetized with xylocaine (an anesthetic similar to that used by dentists), and a very sharp needle is used to sample the bone marrow for evaluation. Bone marrow biopsy and aspiration can have side effects of pain and/or bleeding into the skin and soft tissues at the site of the procedure. Rarely the area at the biopsy site can become infected, and is treated with antibiotics.
* Genetic testing: Some of the blood drawn from you as part of this study will be used for genetic tests. Genetic tests can help researchers study how health or illness is passed on to you by your parents or from you to your children. Any genetic information collected or discovered about you or your family will be confidential.
* Leukapheresis (only patients 18 years and older) to collect large numbers of certain cells - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm.
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm",
"C": "Arm Label: 1; Type: N/A; Interventions: N/A",
"D": "Arm Label: Reslizumab; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT01287039",
"NCT00436670",
"NCT00001406",
"NCT02452190"
] | 147 |
train
|
NCT00001522
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Population Differences in the Insulin Sensitivity, Resting Energy Expenditure, and Body Composition of Overweight Children and Children of Overweight Parents
Brief Summary: This study focuses on the way weight is gained. Individuals who gain weight primarily in their midsection (visceral weight) are at an increased risk for developing diabetes and high blood pressure.
Research has shown that African Americans suffer more often from high blood pressure, diabetes (non-insulin dependent), and heart disease than Caucasian Americans. These conditions lead to significant numbers of deaths and diseases associated with and made worse by obesity.
African American women in particular suffer from obesity and the associated conditions of obesity more than any other race or gender. However, it is unknown if the conditions seen in African American women are a result of the obesity or differences in their insulin sensitivity, glucose disposal, or fat metabolism.
This study will compare body composition, total and resting energy expenditure, and glucose disposal of obese African American and Caucasian children and of non-obese children of obese African American and Caucasian parents, to characterize the timing and nature of factors that may contribute to the prevalence of obesity and its complications.
Patients participating in this study will be followed for 15 years and be evaluated every 5 years during the study.\<TAB\>
|
{
"A": "Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide",
"B": "Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): N/A",
"C": "N/A",
"D": "Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine"
}
|
C
|
[
"NCT00886626",
"NCT00680979",
"NCT00001522",
"NCT00234832"
] | 148 |
train
|
NCT00001723
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions
Brief Summary: Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life.
African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents.
One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults.
Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Program | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Program; Assigned to Arm(s): 3",
"B": "Arm Label: Depression Prevention; Type: EXPERIMENTAL; Interventions: Other: The Blues Program | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Hey Durham | Intervention Type: OTHER; Name: The Blues Program; Assigned to Arm(s): Depression Prevention | Intervention Type: OTHER; Name: Hey Durham; Assigned to Arm(s): Health Education",
"C": "N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Orlistat; Type: EXPERIMENTAL; Interventions: Drug: Orlistat | Intervention Type: DRUG; Name: Orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
D
|
[
"NCT00081328",
"NCT01425905",
"NCT00001195",
"NCT00001723"
] | 149 |
train
|
NCT00002476
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy plus chemotherapy is more effective than radiation therapy alone in treating patients with advanced head and neck cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients with advanced head and neck cancer.
|
{
"A": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I",
"B": "Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II",
"C": "Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: low-LET cobalt-60 gamma ray therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: low-LET photon therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00095875",
"NCT00004227",
"NCT00002476",
"NCT00273546"
] | 150 |
train
|
NCT00002523
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining radiation therapy and surgery with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare radiation therapy alone before surgery with radiation therapy plus fluorouracil and leucovorin before surgery, with and without fluorouracil and leucovorin after surgery in patients with rectal cancer that can be surgically removed.
|
{
"A": "Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab",
"C": "Arm Label: S-1 and Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 & Oxaliplatin | Arm Label: Capecitabine and Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine & Oxaliplatin | Intervention Type: DRUG; Name: S-1 & Oxaliplatin; Assigned to Arm(s): S-1 and Oxaliplatin | Intervention Type: DRUG; Name: Capecitabine & Oxaliplatin; Assigned to Arm(s): Capecitabine and Oxaliplatin",
"D": "Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI"
}
|
A
|
[
"NCT00002523",
"NCT00700102",
"NCT00677443",
"NCT00561470"
] | 151 |
train
|
NCT00002523
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining radiation therapy and surgery with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare radiation therapy alone before surgery with radiation therapy plus fluorouracil and leucovorin before surgery, with and without fluorouracil and leucovorin after surgery in patients with rectal cancer that can be surgically removed.
|
{
"A": "Arm Label: Treatment (capecitabine, oxaliplatin, radiotherapy, surgery); Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: oxaliplatin, Procedure: neoadjuvant therapy, Radiation: radiation therapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery) | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery) | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)",
"B": "Arm Label: Standard TME surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard TME surgery | Arm Label: Long course concurrent chemoradiation; Type: EXPERIMENTAL; Interventions: Drug: Long course concurrent chemoradiation with capecitabine and radiotherapy | Arm Label: Short course radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Short course radiotherapy | Intervention Type: PROCEDURE; Name: Standard TME surgery; Assigned to Arm(s): Standard TME surgery | Intervention Type: DRUG; Name: Long course concurrent chemoradiation with capecitabine and radiotherapy; Assigned to Arm(s): Long course concurrent chemoradiation | Intervention Type: RADIATION; Name: Short course radiotherapy; Assigned to Arm(s): Short course radiotherapy",
"C": "Arm Label: Chemoradiotherapy+TEM; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine (Xeloda), Radiation: 50.4 Gy, Procedure: Transanal Endoscopic Microsurgery | Arm Label: Total Mesorectal Excision; Type: OTHER; Interventions: Procedure: Total Mesorectal Excision | Intervention Type: DRUG; Name: Capecitabine (Xeloda); Assigned to Arm(s): Chemoradiotherapy+TEM | Intervention Type: RADIATION; Name: 50.4 Gy; Assigned to Arm(s): Chemoradiotherapy+TEM | Intervention Type: PROCEDURE; Name: Transanal Endoscopic Microsurgery; Assigned to Arm(s): Chemoradiotherapy+TEM | Intervention Type: PROCEDURE; Name: Total Mesorectal Excision; Assigned to Arm(s): Total Mesorectal Excision",
"D": "Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00114231",
"NCT02945566",
"NCT01308190",
"NCT00002523"
] | 152 |
train
|
NCT00002540
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
Brief Summary: This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.
|
{
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene",
"C": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prostate Screening; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Medical Examination Assessment, Other: Screening Questionnaire Administration | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Prostate Screening | Intervention Type: PROCEDURE; Name: Medical Examination Assessment; Assigned to Arm(s): Prostate Screening | Intervention Type: OTHER; Name: Screening Questionnaire Administration; Assigned to Arm(s): Prostate Screening",
"D": "Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo"
}
|
C
|
[
"NCT00000611",
"NCT00270647",
"NCT00002540",
"NCT00006392"
] | 153 |
train
|
NCT00002561
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, with or without chemotherapy, with chemotherapy alone in treating patients with stage I or stage IIA Hodgkin's disease.
|
{
"A": "Arm Label: Arm A (ABVD); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Bleomycin, Drug: Vinblastine, Drug: Dacarbazine, Radiation: Radiotherapy | Arm Label: Arm B (Stanford V); Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxorubicin, Drug: Bleomycin, Drug: Vinblastine, Drug: Vincristine, Drug: Mechlorethamine, Drug: Etoposide, Drug: Prednisone, Drug: Cyclophosphamide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V) | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V) | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Arm A (ABVD) | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Mechlorethamine; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V)",
"B": "Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D",
"C": "Arm Label: Radiotherapy or ABVD + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine, Radiation: radiation therapy | Arm Label: ABVD Alone; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiotherapy or ABVD + Radiotherapy",
"D": "Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mechlorethamine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00003389",
"NCT00265018",
"NCT00002561",
"NCT00379041"
] | 154 |
train
|
NCT00002561
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, with or without chemotherapy, with chemotherapy alone in treating patients with stage I or stage IIA Hodgkin's disease.
|
{
"A": "Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome",
"B": "Arm Label: Arm I (Patients off-therapy before callback-Induction only); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm II (RER with CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm III (RER with CR [ABVE-PC]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm IV (RER with less than CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm V (RER with PD); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VI (SER [DECA, ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VII (SER [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: RADIATION; Name: Involved-Field Radiation Therapy; Assigned to Arm(s): Arm II (RER with CR [ABVE-PC, IFRT]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Vincristine Sulfate Liposome; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT])",
"C": "Arm Label: Radiotherapy or ABVD + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine, Radiation: radiation therapy | Arm Label: ABVD Alone; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiotherapy or ABVD + Radiotherapy",
"D": "Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II"
}
|
C
|
[
"NCT00433433",
"NCT00025259",
"NCT00002561",
"NCT00943423"
] | 155 |
train
|
NCT00002569
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
|
{
"A": "Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Radiation therapy; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Arm Label: Radiation plus PCV chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiation plus PCV chemotherapy, Radiation therapy",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Conformal radiotherapy | Arm Label: 2; Type: OTHER; Interventions: Radiation: Conventional radiotherapy | Intervention Type: RADIATION; Name: Stereotactic Conformal radiotherapy; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): 2",
"C": "Arm Label: Radiation therapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: Intensive pre-treatment chemotherapy and radiation therapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy, Radiation therapy (RT) alone",
"D": "Arm Label: radiotherapy; Type: OTHER; Interventions: Radiation: radiation therapy | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): radiotherapy"
}
|
C
|
[
"NCT00003375",
"NCT00517959",
"NCT00002569",
"NCT00182819"
] | 156 |
train
|
NCT00002569
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
|
{
"A": "Arm Label: Radiation therapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: Intensive pre-treatment chemotherapy and radiation therapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy, Radiation therapy (RT) alone",
"B": "Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy",
"C": "Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Radiotherapy; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00002569",
"NCT01450449",
"NCT00006353",
"NCT00430911"
] | 157 |
train
|
NCT00002641
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in treating soft tissue sarcoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without chemotherapy in treating patients who have soft tissue sarcoma.
|
{
"A": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Group 2, arm I; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Group 2, arm II; Type: EXPERIMENTAL; Interventions: Biological: dactinomycin, Drug: busulfan, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: melphalan, Drug: vincristine sulfate, Procedure: autologous hematopoietic stem cell transplantation, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: dactinomycin; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): Group 2, arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 2, arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 2, arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Group 1, Group 2, arm I, Group 2, arm II",
"B": "Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Arm Label: Regimen B; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: brachytherapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Regimen A, Regimen B",
"C": "Arm Label: Trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Trabectedin | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine",
"D": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: isolated perfusion; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00020566",
"NCT00006734",
"NCT01343277",
"NCT00002641"
] | 158 |
train
|
NCT00002720
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS
Brief Summary: RATIONALE: Surgery to remove axillary lymph nodes may be an effective treatment for women with breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of therapy with or without axillary lymph node dissection following quadrantectomy in treating older women with stage I breast cancer that is estrogen receptor positive.
|
{
"A": "Arm Label: Arm I: Conventional axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional surgery | Arm Label: Arm II: Sentinel node resection followed by node examination; Type: EXPERIMENTAL; Interventions: Procedure: Sentinel node resection followed by node examination | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I: Conventional axillary dissection | Intervention Type: PROCEDURE; Name: Sentinel node resection followed by node examination; Assigned to Arm(s): Arm II: Sentinel node resection followed by node examination",
"B": "Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"C": "Arm Label: axillary lymph node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: axillary lymph node dissection, Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery | Arm Label: axillary radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery, Radiation: radiation therapy | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): axillary lymph node dissection | Intervention Type: PROCEDURE; Name: lymphoscintigraphy; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): axillary radiotherapy",
"D": "Arm Label: Axillary Dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary lymph node dissection | Arm Label: No Axillary Dissection; Type: EXPERIMENTAL; Interventions: Procedure: No axillary lymph node dissection | Intervention Type: PROCEDURE; Name: Axillary lymph node dissection; Assigned to Arm(s): Axillary Dissection | Intervention Type: PROCEDURE; Name: No axillary lymph node dissection; Assigned to Arm(s): No Axillary Dissection"
}
|
B
|
[
"NCT00003830",
"NCT00002720",
"NCT00014612",
"NCT00072293"
] | 159 |
train
|
NCT00002803
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA
Brief Summary: RATIONALE: Sometimes neuroblastoma will regress without treatment, but sometimes additional treatment may be necessary. Giving more than one chemotherapy drug after surgery to remove the tumor may kill more tumor cells.
PURPOSE: Phase II trial to study combination chemotherapy or observation following surgery in treating infants with neuroblastoma.
|
{
"A": "Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT",
"B": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"C": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT01704716",
"NCT00365755",
"NCT00017225",
"NCT00002803"
] | 160 |
train
|
NCT00002803
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA
Brief Summary: RATIONALE: Sometimes neuroblastoma will regress without treatment, but sometimes additional treatment may be necessary. Giving more than one chemotherapy drug after surgery to remove the tumor may kill more tumor cells.
PURPOSE: Phase II trial to study combination chemotherapy or observation following surgery in treating infants with neuroblastoma.
|
{
"A": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"B": "Arm Label: Arm I (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Arm Label: Arm II (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm I (unpurged PBSC collection) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: isotretinoin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: topotecan hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: bone marrow ablation with stem cell support; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection)",
"C": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"D": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00365755",
"NCT00004188",
"NCT00002803",
"NCT00017225"
] | 161 |
train
|
NCT00002840
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, and may be an effective treatment for anaplastic oligodendroglioma. Combining combination chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare radiation therapy with and without combination chemotherapy in patients with resected anaplastic oligodendroglioma.
|
{
"A": "Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: Radiation therapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: Intensive pre-treatment chemotherapy and radiation therapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy, Radiation therapy (RT) alone",
"C": "Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"D": "Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation"
}
|
C
|
[
"NCT00006353",
"NCT00002569",
"NCT00002840",
"NCT00482677"
] | 162 |
train
|
NCT00002899
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial on Convergent Beam Irradiation of Cerebral Metastases
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Adjuvant radiation therapy may kill any remaining tumor cells following surgery or radiosurgery for brain metastases.
PURPOSE: This randomized phase III trial is studying surgery or radiosurgery alone to see how well it works compared to surgery or radiosurgery and whole-brain radiation therapy in treating brain metastases in patients with solid tumors.
|
{
"A": "Arm Label: Arm I - WBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole-brain radiation therapy | Arm Label: Arm II - SRS; Type: EXPERIMENTAL; Interventions: Radiation: stereotactic radiosurgery | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): Arm II - SRS | Intervention Type: RADIATION; Name: whole-brain radiation therapy; Assigned to Arm(s): Arm I - WBRT",
"B": "Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): N/A",
"C": "Arm Label: Surgery + Whole Brain Radiotherapy; Type: OTHER; Interventions: Procedure: Surgery + WBRT | Arm Label: RadioSurgery + Whole Brain Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiosurgery + WBRT | Intervention Type: PROCEDURE; Name: Surgery + WBRT; Assigned to Arm(s): Surgery + Whole Brain Radiotherapy | Intervention Type: RADIATION; Name: Radiosurgery + WBRT; Assigned to Arm(s): RadioSurgery + Whole Brain Radiotherapy",
"D": "Arm Label: Arm I (SRS); Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Radiosurgery | Arm Label: Arm II (observation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: Stereotactic Radiosurgery; Assigned to Arm(s): Arm I (SRS)"
}
|
B
|
[
"NCT01372774",
"NCT00002899",
"NCT00124761",
"NCT00950001"
] | 163 |
train
|
NCT00003232
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain
Brief Summary: RATIONALE: Some drugs used in chemotherapy can reduce the pain experienced by some people with cancer. Combining more than one drug may be more effective at reducing cancer pain. It is not known whether receiving combination chemotherapy with clodronate is more effective than receiving combination chemotherapy without clodronate for hormone refractory metastatic prostate cancer.
PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of combination chemotherapy using mitoxantrone plus prednisone with or without clodronate in treating pain in patients with hormone refractory metastatic prostate cancer.
|
{
"A": "Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Risedronate | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm",
"B": "Intervention Type: DRUG; Name: alendronate sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ketoconazole; Assigned to Arm(s): N/A",
"C": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: antiandrogen therapy, Drug: zoledronic acid | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: antiandrogen therapy | Intervention Type: DRUG; Name: antiandrogen therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Arm I",
"D": "Intervention Type: DRUG; Name: clodronate disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mitoxantrone hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00216060",
"NCT00019695",
"NCT00685646",
"NCT00003232"
] | 164 |
train
|
NCT00003375
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy combined with chemotherapy is more effective than radiation therapy alone in treating patients with low-grade glioma.
PURPOSE: Phase II/III trial to evaluate observation and to compare the effectiveness of radiation therapy with or without combination chemotherapy in treating patients with low-grade glioma.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Conformal radiotherapy | Arm Label: 2; Type: OTHER; Interventions: Radiation: Conventional radiotherapy | Intervention Type: RADIATION; Name: Stereotactic Conformal radiotherapy; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): 2",
"B": "Arm Label: radiotherapy; Type: OTHER; Interventions: Radiation: radiation therapy | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): radiotherapy",
"C": "Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Radiation therapy; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Arm Label: Radiation plus PCV chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiation plus PCV chemotherapy, Radiation therapy",
"D": "Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Biological: CAN-2409, Drug: Valacyclovir, Drug: Temozolomide, Radiation: Radiation therapy | Intervention Type: BIOLOGICAL; Name: CAN-2409; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Single arm | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Single arm"
}
|
C
|
[
"NCT00517959",
"NCT00182819",
"NCT00003375",
"NCT00589875"
] | 165 |
train
|
NCT00003389
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.
|
{
"A": "Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D",
"B": "Arm Label: Arm A (ABVD); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Bleomycin, Drug: Vinblastine, Drug: Dacarbazine, Radiation: Radiotherapy | Arm Label: Arm B (Stanford V); Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxorubicin, Drug: Bleomycin, Drug: Vinblastine, Drug: Vincristine, Drug: Mechlorethamine, Drug: Etoposide, Drug: Prednisone, Drug: Cyclophosphamide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V) | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V) | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Arm A (ABVD) | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Mechlorethamine; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (Stanford V) | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm A (ABVD), Arm B (Stanford V)",
"C": "Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mechlorethamine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"D": "Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome"
}
|
B
|
[
"NCT00265018",
"NCT00003389",
"NCT00379041",
"NCT00433433"
] | 166 |
train
|
NCT00003636
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after surgery with or without additional surgery in treating patients with stage III or stage IV ovarian cancer, peritoneal cancer, or fallopian tube cancer.
|
{
"A": "Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX",
"B": "Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery",
"C": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A",
"D": "Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)"
}
|
C
|
[
"NCT02828618",
"NCT01461850",
"NCT00003636",
"NCT00262847"
] | 167 |
train
|
NCT00003636
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after surgery with or without additional surgery in treating patients with stage III or stage IV ovarian cancer, peritoneal cancer, or fallopian tube cancer.
|
{
"A": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1",
"C": "Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: MM-121 (SAR256212) + Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: MM-121, Drug: Paclitaxel | Intervention Type: DRUG; Name: MM-121; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel, Paclitaxel",
"D": "Arm Label: open label; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): open label | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): open label"
}
|
A
|
[
"NCT00003636",
"NCT00862836",
"NCT01447706",
"NCT00696670"
] | 168 |
train
|
NCT00003636
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after surgery with or without additional surgery in treating patients with stage III or stage IV ovarian cancer, peritoneal cancer, or fallopian tube cancer.
|
{
"A": "Arm Label: Arm I PDS and chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDS (Primary Debulkdung Surgery), Procedure: 6 cycles of standard chemotherapy | Arm Label: Arm II Timing of surgery after 3 cycles of SOC CTX; Type: EXPERIMENTAL; Interventions: Procedure: Timing of surgery after 3 cycles of standard NACT, IDS, Procedure: IDS, Drug: 3 cycles of standard chemotherapy | Intervention Type: PROCEDURE; Name: PDS (Primary Debulkdung Surgery); Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: 6 cycles of standard chemotherapy; Assigned to Arm(s): Arm I PDS and chemotherapy | Intervention Type: PROCEDURE; Name: Timing of surgery after 3 cycles of standard NACT, IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: PROCEDURE; Name: IDS; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX | Intervention Type: DRUG; Name: 3 cycles of standard chemotherapy; Assigned to Arm(s): Arm II Timing of surgery after 3 cycles of SOC CTX",
"B": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No Lymphadenectomy (LNE) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Lymphadenectomy (LNE) | Intervention Type: PROCEDURE; Name: No Lymphadenectomy (LNE); Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Lymphadenectomy (LNE); Assigned to Arm(s): B",
"D": "Arm Label: Primary debulking surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary Debulking Surgery + Adjuvant Chemotherapy | Arm Label: Interval debulking surgery; Type: EXPERIMENTAL; Interventions: Drug: Neoadjuvant chemotherapy + Interval Debulking Surgery | Intervention Type: DRUG; Name: Neoadjuvant chemotherapy + Interval Debulking Surgery; Assigned to Arm(s): Interval debulking surgery | Intervention Type: PROCEDURE; Name: Primary Debulking Surgery + Adjuvant Chemotherapy; Assigned to Arm(s): Primary debulking surgery"
}
|
B
|
[
"NCT02828618",
"NCT00003636",
"NCT00712218",
"NCT01461850"
] | 169 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group",
"B": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"C": "Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)",
"D": "Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT01634841",
"NCT00003787",
"NCT01005498",
"NCT00274729"
] | 170 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A",
"B": "Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics",
"C": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"D": "Arm Label: Low Carb; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low- Carbohydrate -Atkins Diet | Arm Label: Low Calorie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Calorie Diet | Intervention Type: BEHAVIORAL; Name: Low- Carbohydrate -Atkins Diet; Assigned to Arm(s): Low Carb | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet; Assigned to Arm(s): Low Calorie"
}
|
C
|
[
"NCT00124553",
"NCT00167700",
"NCT00003787",
"NCT00143936"
] | 171 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A",
"C": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"D": "Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00000611",
"NCT00124553",
"NCT00003787",
"NCT00160108"
] | 172 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3",
"C": "Arm Label: Cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention"
}
|
D
|
[
"NCT00000611",
"NCT00352170",
"NCT01166165",
"NCT00003787"
] | 173 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2",
"C": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00003787",
"NCT00276939",
"NCT00622960",
"NCT00000611"
] | 174 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline",
"B": "Arm Label: Exercise under observation; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and exercise under observation | Arm Label: General advice on exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and general advice on exercise | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and exercise under observation; Assigned to Arm(s): Exercise under observation | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and general advice on exercise; Assigned to Arm(s): General advice on exercise",
"C": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet",
"D": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention"
}
|
D
|
[
"NCT02062424",
"NCT01513798",
"NCT00622960",
"NCT00003787"
] | 175 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Arm Label: dietary; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary | Arm Label: physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: dietary and physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, Behavioral: Physical activity | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary; Assigned to Arm(s): dietary, dietary and physical activity | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): dietary and physical activity, physical activity",
"B": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"C": "Arm Label: Experimetal Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored health partnership program | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: Behavioral: Usual care and health education workshop | Intervention Type: BEHAVIORAL; Name: Tailored health partnership program; Assigned to Arm(s): Experimetal Arm | Intervention Type: BEHAVIORAL; Name: Usual care and health education workshop; Assigned to Arm(s): Control Arm",
"D": "Arm Label: Web-based, Stage-matched Exercise and Diet Planning program; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based Health Planner on diet and exercise | Arm Label: Non-tailored booklet on exercise and diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-tailored booklet on exercise and diet | Intervention Type: BEHAVIORAL; Name: Web-based Health Planner on diet and exercise; Assigned to Arm(s): Web-based, Stage-matched Exercise and Diet Planning program | Intervention Type: BEHAVIORAL; Name: Non-tailored booklet on exercise and diet; Assigned to Arm(s): Non-tailored booklet on exercise and diet"
}
|
B
|
[
"NCT01708824",
"NCT00003787",
"NCT01527409",
"NCT01512069"
] | 176 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A",
"C": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"D": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet"
}
|
C
|
[
"NCT00160108",
"NCT00000616",
"NCT00003787",
"NCT00622960"
] | 177 |
train
|
NCT00003787
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Brief Summary: RATIONALE: Dietary fats, fruits, vegetables, and fiber may affect the risk of breast cancer recurrence.
PURPOSE: Randomized clinical trial to determine the effectiveness of a diet rich in vegetables, fruit, and fiber and low in fat in women who have been treated for stage I, stage II, or stage III breast cancer.
|
{
"A": "Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)",
"B": "Arm Label: Lymphedema Care Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise only; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Weight loss only; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Loss Intervention | Arm Label: Exercise and Weight loss combined; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Behavioral: Weight Loss Intervention | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Exercise only | Intervention Type: BEHAVIORAL; Name: Weight Loss Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Weight loss only",
"C": "Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling",
"D": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention"
}
|
D
|
[
"NCT02056067",
"NCT01515124",
"NCT00303875",
"NCT00003787"
] | 178 |
train
|
NCT00003830
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients
Brief Summary: RATIONALE: Removing the sentinel lymph nodes and examining them under a microscope may help plan more effective surgery for breast cancer. It is not yet known if surgery to remove the sentinel lymph nodes is more effective with or without removal of the lymph nodes in the armpit in treating breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of surgery to remove the sentinel lymph nodes with or without removal of lymph nodes in the armpit in treating women who have breast cancer.
|
{
"A": "Arm Label: Arm I: Conventional axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional surgery | Arm Label: Arm II: Sentinel node resection followed by node examination; Type: EXPERIMENTAL; Interventions: Procedure: Sentinel node resection followed by node examination | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I: Conventional axillary dissection | Intervention Type: PROCEDURE; Name: Sentinel node resection followed by node examination; Assigned to Arm(s): Arm II: Sentinel node resection followed by node examination",
"B": "Arm Label: axillary lymph node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: axillary lymph node dissection, Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery | Arm Label: axillary radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery, Radiation: radiation therapy | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): axillary lymph node dissection | Intervention Type: PROCEDURE; Name: lymphoscintigraphy; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): axillary radiotherapy",
"C": "Arm Label: Axillary Dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary lymph node dissection | Arm Label: No Axillary Dissection; Type: EXPERIMENTAL; Interventions: Procedure: No axillary lymph node dissection | Intervention Type: PROCEDURE; Name: Axillary lymph node dissection; Assigned to Arm(s): Axillary Dissection | Intervention Type: PROCEDURE; Name: No axillary lymph node dissection; Assigned to Arm(s): No Axillary Dissection",
"D": "Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00003830",
"NCT00014612",
"NCT00072293",
"NCT00210236"
] | 179 |
train
|
NCT00003855
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Brief Summary: RATIONALE: Surgery to remove lymph nodes in the armpit may remove cancer cells that have spread from tumors in the breast.
PURPOSE: Randomized phase III trial to determine the effectiveness of removing lymph nodes in the armpit in treating women who have stage I or stage IIA breast cancer.
|
{
"A": "Arm Label: Axillary Dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary lymph node dissection | Arm Label: No Axillary Dissection; Type: EXPERIMENTAL; Interventions: Procedure: No axillary lymph node dissection | Intervention Type: PROCEDURE; Name: Axillary lymph node dissection; Assigned to Arm(s): Axillary Dissection | Intervention Type: PROCEDURE; Name: No axillary lymph node dissection; Assigned to Arm(s): No Axillary Dissection",
"B": "Arm Label: axillary lymph node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: axillary lymph node dissection, Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery | Arm Label: axillary radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery, Radiation: radiation therapy | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): axillary lymph node dissection | Intervention Type: PROCEDURE; Name: lymphoscintigraphy; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): axillary radiotherapy",
"C": "Arm Label: Surgery + radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: axillary lymph node dissection, Radiation: whole breast irradiation | Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole breast irradiation | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): Surgery + radiotherapy | Intervention Type: RADIATION; Name: whole breast irradiation; Assigned to Arm(s): Radiotherapy, Surgery + radiotherapy",
"D": "Arm Label: Arm I: Conventional axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional surgery | Arm Label: Arm II: Sentinel node resection followed by node examination; Type: EXPERIMENTAL; Interventions: Procedure: Sentinel node resection followed by node examination | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I: Conventional axillary dissection | Intervention Type: PROCEDURE; Name: Sentinel node resection followed by node examination; Assigned to Arm(s): Arm II: Sentinel node resection followed by node examination"
}
|
C
|
[
"NCT00072293",
"NCT00014612",
"NCT00003855",
"NCT00003830"
] | 180 |
train
|
NCT00003888
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for advanced head and neck cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy plus radiation therapy in treating patients who have advanced head and neck cancer.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, 5-fluorouracil (5-FU), radiotherapy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Cisplatin + radiotherapy | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Cisplatin, 5-fluorouracil (5-FU), radiotherapy; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Cisplatin + radiotherapy; Assigned to Arm(s): 3",
"B": "Arm Label: Reduced RT + Pacitaxel/Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel/Cisplatin, Radiation: Reduced RT | Arm Label: Standard RT + 5-Fluorouracil/Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU/Cisplatin, Radiation: Standard RT | Intervention Type: DRUG; Name: Paclitaxel/Cisplatin; Assigned to Arm(s): Reduced RT + Pacitaxel/Cisplatin | Intervention Type: RADIATION; Name: Reduced RT; Assigned to Arm(s): Reduced RT + Pacitaxel/Cisplatin | Intervention Type: DRUG; Name: 5-FU/Cisplatin; Assigned to Arm(s): Standard RT + 5-Fluorouracil/Cisplatin | Intervention Type: RADIATION; Name: Standard RT; Assigned to Arm(s): Standard RT + 5-Fluorouracil/Cisplatin",
"C": "Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"D": "Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II"
}
|
C
|
[
"NCT00261703",
"NCT01126216",
"NCT00003888",
"NCT00004227"
] | 181 |
train
|
NCT00003906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells.
PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that of tamoxifen in preventing breast cancer in postmenopausal women.
|
{
"A": "Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamoxifen | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Raloxifene | Intervention Type: DRUG; Name: Raloxifene; Assigned to Arm(s): Group 2 | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): Group 1",
"B": "Arm Label: Arm I (2.5 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Arm Label: Arm II (1.0 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Arm Label: Arm III (0.25 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Arm Label: Arm IV (2.5 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Arm I (2.5 mg letrozole), Arm II (1.0 mg letrozole), Arm III (0.25 mg letrozole), Arm IV (2.5 mg letrozole) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (2.5 mg letrozole), Arm II (1.0 mg letrozole), Arm III (0.25 mg letrozole), Arm IV (2.5 mg letrozole) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (2.5 mg letrozole), Arm II (1.0 mg letrozole), Arm III (0.25 mg letrozole), Arm IV (2.5 mg letrozole)",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tibolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tibolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2"
}
|
A
|
[
"NCT00003906",
"NCT01077453",
"NCT00000479",
"NCT00519857"
] | 182 |
train
|
NCT00004067
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer.
PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy together with trastuzumab works compared to combination chemotherapy alone in treating women with node-positive stage II or stage IIIA breast cancer that overexpresses HER2.
|
{
"A": "Arm Label: Arm 1: adriamycin + cyclophosphamide then taxol; Type: ACTIVE_COMPARATOR; Interventions: Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Arm Label: Arm 2: adriamycin + cyclophosphamide then taxol + herceptin; Type: EXPERIMENTAL; Interventions: Biological: herceptin, Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Intervention Type: BIOLOGICAL; Name: herceptin; Assigned to Arm(s): Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: adriamycin; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: taxol; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin",
"B": "Arm Label: Arm I (HF-WBI); Type: EXPERIMENTAL; Interventions: Radiation: External Beam Radiation Therapy, Radiation: Hypofractionated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Radiation: Whole Breast Irradiation | Arm Label: Arm II (CF-WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: External Beam Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Radiation: Whole Breast Irradiation | Intervention Type: RADIATION; Name: External Beam Radiation Therapy; Assigned to Arm(s): Arm I (HF-WBI) | Intervention Type: RADIATION; Name: External Beam Radiation Therapy; Assigned to Arm(s): Arm II (CF-WBI) | Intervention Type: RADIATION; Name: Hypofractionated Radiation Therapy; Assigned to Arm(s): Arm I (HF-WBI) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (HF-WBI), Arm II (CF-WBI) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (HF-WBI), Arm II (CF-WBI) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (HF-WBI), Arm II (CF-WBI) | Intervention Type: RADIATION; Name: Whole Breast Irradiation; Assigned to Arm(s): Arm I (HF-WBI) | Intervention Type: RADIATION; Name: Whole Breast Irradiation; Assigned to Arm(s): Arm II (CF-WBI)",
"C": "Arm Label: Conventional radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional radiotherapy | Arm Label: Tomotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Tomotherapy | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): Conventional radiotherapy | Intervention Type: RADIATION; Name: Tomotherapy; Assigned to Arm(s): Tomotherapy",
"D": "Arm Label: Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate | Arm Label: Arm II (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Arm Label: Arm III (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Intervention Type: DRUG; Name: Aromatase Inhibition Therapy; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Tamoxifen Citrate; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: BIOLOGICAL; Name: Trastuzumab; Assigned to Arm(s): Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen)"
}
|
A
|
[
"NCT00004067",
"NCT01266642",
"NCT00459628",
"NCT00005970"
] | 183 |
train
|
NCT00004067
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer.
PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy together with trastuzumab works compared to combination chemotherapy alone in treating women with node-positive stage II or stage IIIA breast cancer that overexpresses HER2.
|
{
"A": "Arm Label: Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate | Arm Label: Arm II (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Arm Label: Arm III (AC, paclitaxel, trastuzumab, tamoxifen); Type: EXPERIMENTAL; Interventions: Drug: Aromatase Inhibition Therapy, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Tamoxifen Citrate, Biological: Trastuzumab | Intervention Type: DRUG; Name: Aromatase Inhibition Therapy; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: DRUG; Name: Tamoxifen Citrate; Assigned to Arm(s): Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor), Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen) | Intervention Type: BIOLOGICAL; Name: Trastuzumab; Assigned to Arm(s): Arm II (AC, paclitaxel, trastuzumab, tamoxifen), Arm III (AC, paclitaxel, trastuzumab, tamoxifen)",
"B": "Arm Label: Arm 1: adriamycin + cyclophosphamide then taxol; Type: ACTIVE_COMPARATOR; Interventions: Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Arm Label: Arm 2: adriamycin + cyclophosphamide then taxol + herceptin; Type: EXPERIMENTAL; Interventions: Biological: herceptin, Drug: adriamycin, Drug: cyclophosphamide, Drug: taxol | Intervention Type: BIOLOGICAL; Name: herceptin; Assigned to Arm(s): Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: adriamycin; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin | Intervention Type: DRUG; Name: taxol; Assigned to Arm(s): Arm 1: adriamycin + cyclophosphamide then taxol, Arm 2: adriamycin + cyclophosphamide then taxol + herceptin",
"C": "Arm Label: Observation Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herceptin 1-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Arm Label: Herceptin 2-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 1-Year Arm | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 2-Year Arm",
"D": "Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aromatase inhibition therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: releasing hormone agonist therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00005970",
"NCT00004067",
"NCT00045032",
"NCT00629278"
] | 184 |
train
|
NCT00004125
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes.
|
{
"A": "Arm Label: A:Paclitaxel + Carboplatin every 3 weeks; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin every 3 weeks | Arm Label: B:Carboplatin monotherapy every 3 weeks; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin monotherapy every 3 weeks | Arm Label: C:Weekly Paclitaxel and Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Weekly Paclitaxel and Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin every 3 weeks; Assigned to Arm(s): A:Paclitaxel + Carboplatin every 3 weeks | Intervention Type: DRUG; Name: Carboplatin monotherapy every 3 weeks; Assigned to Arm(s): B:Carboplatin monotherapy every 3 weeks | Intervention Type: DRUG; Name: Weekly Paclitaxel and Carboplatin; Assigned to Arm(s): C:Weekly Paclitaxel and Carboplatin",
"B": "Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: secondary debulking with intraperitoneal chemotherapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Secondary debulking | Intervention Type: PROCEDURE; Name: Secondary debulking; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: secondary debulking with intraperitoneal chemotherapy; Assigned to Arm(s): 1",
"D": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT02001272",
"NCT00262847",
"NCT00426257",
"NCT00004125"
] | 185 |
train
|
NCT00004125
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes.
|
{
"A": "Arm Label: Arm I (CA for 4 courses); Type: ACTIVE_COMPARATOR; Interventions: Drug: AC regimen, Drug: doxorubicin hydrochloride | Arm Label: Arm II (CA for 6 courses [closed to accrual 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride | Arm Label: Arm III (paclitaxel for 4 courses); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Arm Label: Arm IV (paclitaxel for 6 courses [closed 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Intervention Type: DRUG; Name: AC regimen; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]), Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007]) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007])",
"B": "Arm Label: Arm A Taxane-containing; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Arm B standard anthracyclin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): Arm A Taxane-containing, Arm B standard anthracyclin",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: methotrexate, Drug: 5-fluorouracil | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): A",
"D": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00041119",
"NCT01222052",
"NCT00331097",
"NCT00004125"
] | 186 |
train
|
NCT00004188
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
|
{
"A": "Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT",
"B": "Arm Label: Arm I (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Arm Label: Arm II (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm I (unpurged PBSC collection) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: isotretinoin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: topotecan hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: bone marrow ablation with stem cell support; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection)",
"C": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"D": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT01704716",
"NCT00004188",
"NCT00002803",
"NCT00017225"
] | 187 |
train
|
NCT00004188
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
|
{
"A": "Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"B": "Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A",
"D": "Arm Label: Arm I (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Arm Label: Arm II (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm I (unpurged PBSC collection) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: isotretinoin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: topotecan hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: bone marrow ablation with stem cell support; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection)"
}
|
D
|
[
"NCT00002803",
"NCT00017225",
"NCT00365755",
"NCT00004188"
] | 188 |
train
|
NCT00004205
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer.
PURPOSE: Randomized double-blind phase III trial to compare the effectiveness of letrozole with that of tamoxifen in treating postmenopausal women who have breast cancer that has been surgically removed.
|
{
"A": "Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole",
"B": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: testosterone | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: testosterone; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II",
"C": "Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)",
"D": "Arm Label: Tamoxifen; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Tamoxifen | Arm Label: T+OFS; Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Tamoxifen, Drug: Triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: Exemestane, Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Triptorelin | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): E+OFS | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: PROCEDURE; Name: Oophorectomy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): T+OFS, Tamoxifen | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): E+OFS, T+OFS"
}
|
A
|
[
"NCT00004205",
"NCT01573442",
"NCT00489411",
"NCT00066690"
] | 189 |
train
|
NCT00004227
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
|
{
"A": "Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radiotherapy 70 Gy, 35 fractions; Assigned to Arm(s): N/A",
"B": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy (IMRT); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Group 1, Group 2",
"C": "Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II",
"D": "Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone"
}
|
C
|
[
"NCT00169247",
"NCT01084083",
"NCT00004227",
"NCT00122460"
] | 190 |
train
|
NCT00004227
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
|
{
"A": "Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: Induction chemotherapy + concurrent chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Arm Label: Concurrent radiochemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Intervention Type: PROCEDURE; Name: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy; Assigned to Arm(s): Concurrent radiochemotherapy alone, Induction chemotherapy + concurrent chemoradiotherapy",
"C": "Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II",
"D": "Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Cetuximab/Methotrexate/Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab, Drug: Methotrexate, Drug: Docetaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel"
}
|
C
|
[
"NCT00003888",
"NCT00828386",
"NCT00004227",
"NCT02105636"
] | 191 |
train
|
NCT00004227
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
|
{
"A": "Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II",
"B": "Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Dasatinib + Placebo | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib plus Dasatinib | Arm Label: Arm D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dasatinib + Placebo; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Erlotinib plus Dasatinib; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm D | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A",
"C": "Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin",
"D": "Arm Label: Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer); Type: EXPERIMENTAL; Interventions: Drug: erlotinib hydrochloride, Drug: cisplatin, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy, Procedure: quality-of-life assessment | Arm Label: Arm II (chemotherapy, radiotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy, Procedure: quality-of-life assessment | Intervention Type: DRUG; Name: erlotinib hydrochloride; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy)"
}
|
A
|
[
"NCT00004227",
"NCT00779389",
"NCT00169221",
"NCT00410826"
] | 192 |
train
|
NCT00004428
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis.
II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h",
"B": "Arm Label: Cohort A: GLPG2222 50 mg once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 50 mg, Drug: Placebo | Arm Label: Cohort A: GLPG2222 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 100 mg, Drug: Placebo | Arm Label: Cohort B: GLPG2222 200 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 200 mg | Arm Label: Cohort B: GLPG2222 400 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 400 mg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 50 mg; Assigned to Arm(s): Cohort A: GLPG2222 50 mg once daily (QD) | Intervention Type: DRUG; Name: GLPG2222 100 mg; Assigned to Arm(s): Cohort A: GLPG2222 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort A: GLPG2222 100 mg QD, Cohort A: GLPG2222 50 mg once daily (QD), Cohort B Placebo, Cohort B: GLPG2222 200 mg QD, Cohort B: GLPG2222 400 mg QD | Intervention Type: DRUG; Name: GLPG2222 200 mg; Assigned to Arm(s): Cohort B: GLPG2222 200 mg QD | Intervention Type: DRUG; Name: GLPG2222 400 mg; Assigned to Arm(s): Cohort B: GLPG2222 400 mg QD",
"C": "Intervention Type: DRUG; Name: CPX; Assigned to Arm(s): N/A",
"D": "Arm Label: Group 1 - 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 2 - 100 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 3 - 200 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 4 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: N91115 | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): Group 1 - 50 mg, Group 2 - 100 mg, Group 3 - 200 mg, Group 4 - Placebo"
}
|
C
|
[
"NCT01807949",
"NCT03119649",
"NCT00004428",
"NCT02275936"
] | 193 |
train
|
NCT00004428
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis.
II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.
|
{
"A": "Intervention Type: DRUG; Name: CPX; Assigned to Arm(s): N/A",
"B": "Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO",
"C": "Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])",
"D": "Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg"
}
|
A
|
[
"NCT00004428",
"NCT00351078",
"NCT00104520",
"NCT00458341"
] | 194 |
train
|
NCT00004465
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated
Brief Summary: OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome.
II. Determine the effect of SYNSORB Pk therapy on the need for the duration of dialysis in these patients.
III. Determine the effect of SYNSORB Pk therapy on the recovery of renal function and resolution of urinary abnormalities in these patients.
|
{
"A": "Arm Label: SYNSORB Pk; Type: EXPERIMENTAL; Interventions: Drug: SYNSORB Pk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SYNSORB Pk; Assigned to Arm(s): SYNSORB Pk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: cαStx1/cαStx2; Type: EXPERIMENTAL; Interventions: Drug: cαStx1/cαStx2 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: cαStx1/cαStx2; Assigned to Arm(s): cαStx1/cαStx2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control",
"C": "Arm Label: Admission/Intravascular Volume Expansion; Type: EXPERIMENTAL; Interventions: Drug: D5-0.9%NS | Arm Label: Outpatient Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Routine home oral rehydration | Intervention Type: DRUG; Name: D5-0.9%NS; Assigned to Arm(s): Admission/Intravascular Volume Expansion | Intervention Type: DRUG; Name: Routine home oral rehydration; Assigned to Arm(s): Outpatient Observation",
"D": "Arm Label: Stage 1 - high treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 1 - Low treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 1 - Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Stage 2 - Selected active treatment arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM004 | Arm Label: Stage 2 - Placebo arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INM004; Assigned to Arm(s): Stage 1 - Low treatment arm, Stage 1 - high treatment arm, Stage 2 - Selected active treatment arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Stage 1 - Placebo arm, Stage 2 - Placebo arm"
}
|
A
|
[
"NCT00004465",
"NCT01252199",
"NCT03275792",
"NCT04132375"
] | 195 |
train
|
NCT00004467
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES:
I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available.
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: N-acetylcysteine (NAC); Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: Sodium Bicarbonate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00004467",
"NCT00334191",
"NCT00211653",
"NCT00332631"
] | 196 |
train
|
NCT00004486
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.
II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.
III. Compare the baseline compulsive severity and treatment outcome in these patients.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: RO5028442 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: RO5028442; Assigned to Arm(s): 1",
"B": "Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A",
"C": "Arm Label: Social Skills Focused CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Social Skills focused CBT | Arm Label: Stress Management/Relaxation Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management/relaxation training | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo drug | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: BEHAVIORAL; Name: Social Skills focused CBT; Assigned to Arm(s): Social Skills Focused CBT | Intervention Type: BEHAVIORAL; Name: Stress management/relaxation training; Assigned to Arm(s): Stress Management/Relaxation Training | Intervention Type: DRUG; Name: placebo drug; Assigned to Arm(s): placebo drug",
"D": "Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin"
}
|
B
|
[
"NCT01474278",
"NCT00004486",
"NCT01914939",
"NCT01944046"
] | 197 |
train
|
NCT00004486
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.
II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.
III. Compare the baseline compulsive severity and treatment outcome in these patients.
|
{
"A": "Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"D": "Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone"
}
|
B
|
[
"NCT01911442",
"NCT00004486",
"NCT00453180",
"NCT01333072"
] | 198 |
train
|
NCT00004486
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.
II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.
III. Compare the baseline compulsive severity and treatment outcome in these patients.
|
{
"A": "Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last",
"B": "Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A",
"C": "Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo"
}
|
B
|
[
"NCT02552147",
"NCT00004486",
"NCT01337687",
"NCT00178503"
] | 199 |
train
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.